Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Emergent BioSolutions Inc.EBS · Entity 5902 | Director | October 07, 2026 | October 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Emergent BioSolutions Inc.
Report date October 07, 2026 · Filed October 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 111,921 |
Reported balance
After 2026-10-07 transaction · row 1
1 source rowRow 1 · 2026-10-07 · Sale · Disposed 17,800 · Balance 111,921 F1: Represents the number of shares sold by the Reporting Person. Shares were sold pursuant to a Rule 10b5-1 trading plan, dated August 11, 2025, for the purpose of satisfying tax obligations relating to the vesting of RSUs on October 2, 2026. F2: The price reported in Column 4 is a weighted average price for sales executed on the same day within a one-dollar price range. These shares were sold in multiple transactions at prices ranging from $6.88 to $7.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares sold by the Reporting Person. Shares were sold pursuant to a Rule 10b5-1 trading plan, dated August 11, 2025, for the purpose of satisfying tax obligations relating to the vesting of RSUs on October 2, 2026.
F2: The price reported in Column 4 is a weighted average price for sales executed on the same day within a one-dollar price range. These shares were sold in multiple transactions at prices ranging from $6.88 to $7.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
TYME TECHNOLOGIES, INC.
Report date September 16, 2022 · Filed September 16, 2022
Section 16 reporting ended · disclosed 2022-09-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option - Option to buySEC Table II · derivative / convertible security · Conversion / exercise price $2.90 · Expires 2028-05-24 | Direct | 0 |
Reported balance
After 2022-09-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-09-16 · Disposition to issuer · Disposed 100,000 · Balance 0 F1: This option was fully vested and assumed by Syros Pharmaceuticals, Inc. ("Syros") in its merger with the issuer and replaced with an option to purchase 4,382 shares of Syros common stock for $66.18 per share, after giving effect to a 1-for-10 reverse stock split by Syros (the "Reverse Split"). |
| Director Stock Option - Option to buySEC Table II · derivative / convertible security · Conversion / exercise price $2.33 · Expires 2028-08-26 | Direct | 0 |
Reported balance
After 2022-09-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-09-16 · Disposition to issuer · Disposed 50,000 · Balance 0 F2: This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 2,191 shares of Syros common stock for $53.17 per share, after giving effect to the Reverse Split. |
| Director Stock Option - Option to buySEC Table II · derivative / convertible security · Conversion / exercise price $1.18 · Expires 2029-08-22 | Direct | 0 |
Reported balance
After 2022-09-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-09-16 · Disposition to issuer · Disposed 50,000 · Balance 0 F3: This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 2,191 shares of Syros common stock for $26.93 per share, after giving effect to the Reverse Split. |
| Director Stock Option - Option to buySEC Table II · derivative / convertible security · Conversion / exercise price $1.22 · Expires 2030-08-19 | Direct | 0 |
Reported balance
After 2022-09-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-09-16 · Disposition to issuer · Disposed 65,000 · Balance 0 F4: This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 2,848 shares of Syros common stock for $27.84 per share, after giving effect to the Reverse Split. |
| Director Stock Option - Option to buySEC Table II · derivative / convertible security · Conversion / exercise price $1.10 · Expires 2031-08-23 | Direct | 0 |
Reported balance
After 2022-09-16 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-09-16 · Disposition to issuer · Disposed 88,000 · Balance 0 F5: This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 3,856 shares of Syros common stock for $25.10 per share, after giving effect to the Reverse Split. |
| Director Stock Option - Option to buySEC Table II · derivative / convertible security · Conversion / exercise price $0.31 · Expires 2032-08-23 | Direct | 0 |
Reported balance
After 2022-09-16 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-09-16 · Disposition to issuer · Disposed 88,000 · Balance 0 F6: This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 3,856 shares of Syros common stock for $7.07 per share, after giving effect to the Reverse Split. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was fully vested and assumed by Syros Pharmaceuticals, Inc. ("Syros") in its merger with the issuer and replaced with an option to purchase 4,382 shares of Syros common stock for $66.18 per share, after giving effect to a 1-for-10 reverse stock split by Syros (the "Reverse Split").
F2: This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 2,191 shares of Syros common stock for $53.17 per share, after giving effect to the Reverse Split.
F3: This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 2,191 shares of Syros common stock for $26.93 per share, after giving effect to the Reverse Split.
F4: This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 2,848 shares of Syros common stock for $27.84 per share, after giving effect to the Reverse Split.
F5: This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 3,856 shares of Syros common stock for $25.10 per share, after giving effect to the Reverse Split.
F6: This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 3,856 shares of Syros common stock for $7.07 per share, after giving effect to the Reverse Split.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 07, 2026 Filed Oct 7, 2026 19:45 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 17,800 | $7.09 | $126,202.00 |
DisclosureSEC source: 0001583098-26-000008 · wk-form4_1791402323.xml · nonDerivative · entry 1 DeGolyer Donald W · CIK 0001583098 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 111,921 F1 · shares: Represents the number of shares sold by the Reporting Person. Shares were sold pursuant to a Rule 10b5-1 trading plan, dated August 11, 2025, for the purpose of satisfying tax obligations relating to the vesting of RSUs on October 2, 2026. F2 · price: The price reported in Column 4 is a weighted average price for sales executed on the same day within a one-dollar price range. These shares were sold in multiple transactions at prices ranging from $6.88 to $7.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| May 01, 2026 Filed May 4, 2026 21:30 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 954 | $8.96 | $8,547.84 |
DisclosureSEC source: 0001583098-26-000004 · wk-form4_1777930221.xml · nonDerivative · entry 3 DeGolyer Donald W · CIK 0001583098 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 129,721 F2 · shares: Represents the number of shares sold by the Reporting Person. Shares were sold pursuant to a Rule 10b5-1 trading plan, dated August 11, 2025, for the purpose of satisfying tax obligations relating to the vesting of RSUs on April 29, 2026. F4 · price: The price reported in Column 4 is a weighted average price for sales executed on the same day within a one-dollar price range. These shares were sold in multiple transactions at prices ranging from $8.80 to $8.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| May 01, 2026 Filed May 4, 2026 21:30 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 14,527 | $8.36 | $121,445.72 |
DisclosureSEC source: 0001583098-26-000004 · wk-form4_1777930221.xml · nonDerivative · entry 2 DeGolyer Donald W · CIK 0001583098 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 130,675 F2 · shares: Represents the number of shares sold by the Reporting Person. Shares were sold pursuant to a Rule 10b5-1 trading plan, dated August 11, 2025, for the purpose of satisfying tax obligations relating to the vesting of RSUs on April 29, 2026. F3 · price: The price reported in Column 4 is a weighted average price for sales executed on the same day within a one-dollar price range. These shares were sold in multiple transactions at prices ranging from $7.78 to $8.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| April 30, 2026 Filed May 4, 2026 21:30 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantStock Option (Right to Buy) · Derivative | 11,296 | $0.00 Strike: $7.99 | $0.00 |
DisclosureSEC source: 0001583098-26-000004 · wk-form4_1777930221.xml · derivative · entry 4 DeGolyer Donald W · CIK 0001583098 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,296 Underlying: Common Stock · 11,296 shares Expires 2033-04-30 F5 · derivative.exercise_date: Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price. F6 · derivative.underlying_shares: The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant. Read SEC document |
| April 30, 2026 Filed May 4, 2026 21:30 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 25,344 | $0.00 | $0.00 |
DisclosureSEC source: 0001583098-26-000004 · wk-form4_1777930221.xml · nonDerivative · entry 1 DeGolyer Donald W · CIK 0001583098 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 145,202 F1 · shares: Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Read SEC document |
| November 10, 2025 Filed Nov 12, 2025 21:13 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 17,801 | $10.54 | $187,622.54 |
DisclosureSEC source: 0001583098-25-000005 · wk-form4_1762981979.xml · nonDerivative · entry 1 DeGolyer Donald W · CIK 0001583098 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,858 F1 · shares: Represents the number of shares sold by the Reporting Person. Shares were sold pursuant to a Rule 10b5-1 trading plan, dated August 11, 2025, for the purpose of satisfying tax obligations relating to the vesting of RSUs on October 2, 2025. F2 · price: For reporting purposes, sales prices within a $1 range have been aggregated and the weighted average sales price has been reported. The price ranges were: $10.33 - $10.79. The Company maintains a record of the transactions and copies will be provided upon request. Read SEC document |
| August 12, 2025 Filed Aug 13, 2025 20:22 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 7,844 | $8.65 | $67,830.99 |
DisclosureSEC source: 0001628280-25-040156 · wk-form4_1755116574.xml · nonDerivative · entry 1 DeGolyer Donald W · CIK 0001583098 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,659 F1 · shares: Represents the number of shares sold by the Reporting Person to satisfy the Reporting Person's tax obligations resulting from the settlement of vested RSUs on May 22, 2025. F2 · price: All shares sold at an exact price of $8.6475. Read SEC document |
| April 30, 2025 Filed May 3, 2025 00:30 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantStock Option (Right to Buy) · Derivative | 15,824 | $0.00 Strike: $5.45 | $0.00 |
DisclosureSEC source: 0001367644-25-000104 · wk-form4_1746232222.xml · derivative · entry 2 DeGolyer Donald W · CIK 0001583098 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,572 Underlying: Common Stock · 15,824 shares Expires 2032-04-29 F2 · derivative.exercise_date: Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price. F3 · derivative.underlying_shares: The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant. Read SEC document |
| April 30, 2025 Filed May 3, 2025 00:30 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 34,403 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-25-000104 · wk-form4_1746232222.xml · nonDerivative · entry 1 DeGolyer Donald W · CIK 0001583098 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 145,503 F1 · shares: Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Read SEC document |
| November 12, 2024 Filed Nov 14, 2024 21:18 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 25,000 | $10.91 | $272,750.00 |
DisclosureSEC source: 0001367644-24-000186 · wk-form4_1731619131.xml · nonDerivative · entry 1 DeGolyer Donald W · CIK 0001583098 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,100 F1 · price: On November 12, 2024, Mr. DeGolyer sold an aggregate of 25,000 shares of Emergent BioSolutions Inc. common stock. For reporting purposes, the sales prices within a $1 range have been aggregated and the weighted average sales price has been reported. The price ranges were: $10.83 - $11.05. The Company maintains a record of the transactions and copies will be provided upon request. Read SEC document |
| May 23, 2024 Filed May 29, 2024 01:41 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantStock Option (Right to Buy) · Derivative | 25,748 | $0.00 Strike: $5.02 | $0.00 |
DisclosureSEC source: 0001367644-24-000087 · wk-form4_1716946853.xml · derivative · entry 2 DeGolyer Donald W · CIK 0001583098 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,748 Underlying: Common Stock · 25,748 shares Expires 2031-05-22 F2 · derivative.exercise_date: Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price. F3 · derivative.underlying_shares: The number of options granted was determined by dividing half of the total non-employee director compensation value by the Black-Scholes value of a single option calculated as of the date of the grant. Read SEC document |
| May 23, 2024 Filed May 29, 2024 01:41 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 17,430 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-24-000087 · wk-form4_1716946853.xml · nonDerivative · entry 1 DeGolyer Donald W · CIK 0001583098 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,100 F1 · shares: Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Read SEC document |
| October 03, 2023 Filed Oct 5, 2023 23:08 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 118,670 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-23-000177 · wk-form4_1696547320.xml · nonDerivative · entry 1 DeGolyer Donald W · CIK 0001583098 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,670 F1 · shares: Consists of restricted stock units granted under the Company's Stock Incentive Plan, as amended and restated. These restricted stock units will vest in three equal installments over a three-year period assuming continued service with the Company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. Read SEC document |
| September 16, 2022 Filed Sep 16, 2022 18:00 UTC | TYME TECHNOLOGIES, INC. TYME · Entity 123718 | Disposition to issuerDirector Stock Option - Option to buy · Derivative | 88,000 | Not disclosed Strike: $0.31 | Not disclosed |
DisclosureSEC source: 0000899243-22-031344 · doc4.xml · derivative · entry 6 DeGolyer Donald W · CIK 0001583098 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 88,000 shares Expires 2032-08-23 F6 · price: This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 3,856 shares of Syros common stock for $7.07 per share, after giving effect to the Reverse Split. F6 · derivative.exercise_date: This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 3,856 shares of Syros common stock for $7.07 per share, after giving effect to the Reverse Split. Read SEC document |
| September 16, 2022 Filed Sep 16, 2022 18:00 UTC | TYME TECHNOLOGIES, INC. TYME · Entity 123718 | Disposition to issuerDirector Stock Option - Option to buy · Derivative | 88,000 | Not disclosed Strike: $1.10 | Not disclosed |
DisclosureSEC source: 0000899243-22-031344 · doc4.xml · derivative · entry 5 DeGolyer Donald W · CIK 0001583098 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 88,000 shares Expires 2031-08-23 F5 · price: This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 3,856 shares of Syros common stock for $25.10 per share, after giving effect to the Reverse Split. F5 · derivative.exercise_date: This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 3,856 shares of Syros common stock for $25.10 per share, after giving effect to the Reverse Split. Read SEC document |
| September 16, 2022 Filed Sep 16, 2022 18:00 UTC | TYME TECHNOLOGIES, INC. TYME · Entity 123718 | Disposition to issuerDirector Stock Option - Option to buy · Derivative | 65,000 | Not disclosed Strike: $1.22 | Not disclosed |
DisclosureSEC source: 0000899243-22-031344 · doc4.xml · derivative · entry 4 DeGolyer Donald W · CIK 0001583098 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 65,000 shares Expires 2030-08-19 F4 · price: This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 2,848 shares of Syros common stock for $27.84 per share, after giving effect to the Reverse Split. F4 · derivative.exercise_date: This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 2,848 shares of Syros common stock for $27.84 per share, after giving effect to the Reverse Split. Read SEC document |
| September 16, 2022 Filed Sep 16, 2022 18:00 UTC | TYME TECHNOLOGIES, INC. TYME · Entity 123718 | Disposition to issuerDirector Stock Option - Option to buy · Derivative | 50,000 | Not disclosed Strike: $1.18 | Not disclosed |
DisclosureSEC source: 0000899243-22-031344 · doc4.xml · derivative · entry 3 DeGolyer Donald W · CIK 0001583098 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2029-08-22 F3 · price: This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 2,191 shares of Syros common stock for $26.93 per share, after giving effect to the Reverse Split. F3 · derivative.exercise_date: This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 2,191 shares of Syros common stock for $26.93 per share, after giving effect to the Reverse Split. Read SEC document |
| September 16, 2022 Filed Sep 16, 2022 18:00 UTC | TYME TECHNOLOGIES, INC. TYME · Entity 123718 | Disposition to issuerDirector Stock Option - Option to buy · Derivative | 50,000 | Not disclosed Strike: $2.33 | Not disclosed |
DisclosureSEC source: 0000899243-22-031344 · doc4.xml · derivative · entry 2 DeGolyer Donald W · CIK 0001583098 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2028-08-26 F2 · price: This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 2,191 shares of Syros common stock for $53.17 per share, after giving effect to the Reverse Split. F2 · derivative.exercise_date: This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 2,191 shares of Syros common stock for $53.17 per share, after giving effect to the Reverse Split. Read SEC document |
| September 16, 2022 Filed Sep 16, 2022 18:00 UTC | TYME TECHNOLOGIES, INC. TYME · Entity 123718 | Disposition to issuerDirector Stock Option - Option to buy · Derivative | 100,000 | Not disclosed Strike: $2.90 | Not disclosed |
DisclosureSEC source: 0000899243-22-031344 · doc4.xml · derivative · entry 1 DeGolyer Donald W · CIK 0001583098 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2028-05-24 F1 · price: This option was fully vested and assumed by Syros Pharmaceuticals, Inc. ("Syros") in its merger with the issuer and replaced with an option to purchase 4,382 shares of Syros common stock for $66.18 per share, after giving effect to a 1-for-10 reverse stock split by Syros (the "Reverse Split"). F1 · derivative.exercise_date: This option was fully vested and assumed by Syros Pharmaceuticals, Inc. ("Syros") in its merger with the issuer and replaced with an option to purchase 4,382 shares of Syros common stock for $66.18 per share, after giving effect to a 1-for-10 reverse stock split by Syros (the "Reverse Split"). Read SEC document |
| August 24, 2022 Filed Aug 29, 2022 06:30 UTC | TYME TECHNOLOGIES, INC. TYME · Entity 123718 | GrantDirector Stock Option - Option to buy · Derivative | 88,000 | $0.00 Strike: $0.31 | $0.00 |
DisclosureSEC source: 0000899243-22-029940 · doc4.xml · derivative · entry 1 DeGolyer Donald W · CIK 0001583098 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,000 Underlying: Common Stock · 88,000 shares Expires 2032-08-23 F1 · derivative.exercise_date: This option vests over a one-year period in equal quarterly installments. Read SEC document |
| August 24, 2021 Filed Aug 26, 2021 16:32 UTC | TYME TECHNOLOGIES, INC. TYME · Entity 123718 | GrantDirector Stock Option - Option to buy · Derivative | 88,000 | $0.00 Strike: $1.10 | $0.00 |
DisclosureSEC source: 0000899243-21-034260 · doc4.xml · derivative · entry 1 DeGolyer Donald W · CIK 0001583098 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,000 Underlying: Common Stock · 88,000 shares Expires 2031-08-23 F1 · derivative.exercise_date: This option vests over a one-year period in equal quarterly installments. Read SEC document |
| August 20, 2020 Filed Aug 24, 2020 17:41 UTC | TYME TECHNOLOGIES, INC. TYME · Entity 123718 | GrantDirector Stock Option - right to buy · Derivative | 65,000 | $0.00 Strike: $1.22 | $0.00 |
DisclosureSEC source: 0000899243-20-023316 · doc4.xml · derivative · entry 1 DeGolyer Donald W · CIK 0001583098 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2020-08-20 F1 · derivative.exercise_date: This option, granted as annual compensation for director service, vests over a one-year period in four equal quarterly installments. Read SEC document |
| August 22, 2019 Filed Aug 27, 2019 09:34 UTC | TYME TECHNOLOGIES, INC. TYME · Entity 123718 | GrantDirector Stock Option - right to buy · Derivative | 50,000 | $0.00 Strike: $1.18 | $0.00 |
DisclosureSEC source: 0000899243-19-022499 · doc4.xml · derivative · entry 1 DeGolyer Donald W · CIK 0001583098 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-08-21 F1 · derivative.exercise_date: This option, granted as annual compensation for director service, vests over a one-year period in four equal quarterly installments. Read SEC document |
| August 26, 2018 Filed Aug 28, 2018 17:01 UTC | TYME TECHNOLOGIES, INC. TYME · Entity 123718 | GrantDirector Stock Option - right to buy · Derivative | 50,000 | $0.00 Strike: $2.33 | $0.00 |
DisclosureSEC source: 0000899243-18-023402 · doc4.xml · derivative · entry 1 DeGolyer Donald W · CIK 0001583098 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2028-08-26 F1 · derivative.exercise_date: This option, granted as annual compensation for director service, vests over a one-year period in four equal quarterly installments. Read SEC document |
| May 24, 2018 Filed May 29, 2018 20:34 UTC | TYME TECHNOLOGIES, INC. TYME · Entity 123718 | GrantDirector Stock Option - right to buy · Derivative | 100,000 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0000899243-18-014359 · doc4.xml · derivative · entry 1 DeGolyer Donald W · CIK 0001583098 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2028-05-24 F1 · derivative.exercise_date: This option grant vests over a one-year period in four equal quarterly installments. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.